Bachem Holding AG (BCHMF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Bachem Holding AG (BCHMF) with AI Score 46/100 (Weak). Bachem Holding AG is a Swiss company specializing in the development, production, and regulatory support of peptide active pharmaceutical ingredients. Market cap: 0, Sector: Basic materials.
Last analyzed: Mar 16, 2026Bachem Holding AG (BCHMF) Materials & Commodity Exposure
Bachem Holding AG, founded in 1971, is a global leader in peptide and oligonucleotide active pharmaceutical ingredients (APIs). The company provides comprehensive services from research to commercial application, serving pharmaceutical and biotechnology companies worldwide. With a strong focus on quality and regulatory compliance, Bachem is positioned to capitalize on the growing demand for peptide-based therapeutics.
Investment Thesis
Bachem Holding AG presents a notable research candidate due to its leading position in the peptide and oligonucleotide API market. The company's strong financial performance, with a profit margin of 21.4% and a gross margin of 28.7%, demonstrates its operational efficiency and pricing power. Bachem's beta of 0.98 indicates a relatively low volatility compared to the overall market. Growth catalysts include the increasing demand for peptide-based therapeutics and the company's expansion into new markets. Bachem's commitment to innovation and its focus on quality and regulatory compliance further enhance its long-term growth prospects. However, potential risks include competition from other API manufacturers and fluctuations in raw material prices. Investors should monitor Bachem's ability to maintain its market share and manage its cost structure effectively.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $5.75 billion reflects investor confidence in Bachem's growth potential.
- P/E ratio of 30.40 indicates a premium valuation, suggesting high expectations for future earnings growth.
- Profit margin of 21.4% demonstrates strong profitability and efficient operations.
- Gross margin of 28.7% highlights Bachem's ability to maintain competitive pricing and manage costs effectively.
- Dividend yield of 1.41% provides a steady income stream for investors.
Competitors & Peers
Strengths
- Leading position in the peptide and oligonucleotide API market.
- Strong focus on quality and regulatory compliance.
- Long-standing relationships with pharmaceutical companies.
- Vertical integration ensures a reliable supply chain.
Weaknesses
- Limited diversification in therapeutic areas.
- Dependence on a relatively small number of key customers.
- Exposure to fluctuations in raw material prices.
- Geographic concentration in Europe.
Catalysts
- Ongoing: Increasing demand for peptide-based therapeutics will drive revenue growth.
- Ongoing: Expansion into new therapeutic areas will diversify revenue streams.
- Upcoming: Potential strategic acquisitions to expand product portfolio (within 3-5 years).
- Ongoing: Strengthening partnerships with pharmaceutical companies will secure long-term supply agreements.
- Ongoing: Investments in research and development will lead to new product innovations (within 2-3 years).
Risks
- Potential: Competition from other API manufacturers could erode market share.
- Potential: Changes in regulatory requirements could increase compliance costs.
- Potential: Economic downturns could affect pharmaceutical spending.
- Potential: Technological advancements could render existing products obsolete.
- Ongoing: Fluctuations in raw material prices could impact profitability.
Growth Opportunities
- Expansion into new therapeutic areas: Bachem can leverage its expertise in peptide and oligonucleotide APIs to expand into new therapeutic areas, such as oncology and immunology. The global market for oncology drugs is projected to reach $286 billion by 2028, presenting a significant growth opportunity for Bachem. By developing and manufacturing APIs for these high-growth therapeutic areas, Bachem can diversify its revenue streams and enhance its long-term growth prospects.
- Increasing demand for peptide-based therapeutics: The increasing demand for peptide-based therapeutics is driving growth in the peptide API market. Peptides offer several advantages over traditional small molecule drugs, including higher specificity and lower toxicity. The global peptide therapeutics market is projected to reach $45 billion by 2027, creating a favorable environment for Bachem. By capitalizing on this trend, Bachem can increase its sales and market share.
- Strategic acquisitions: Bachem can pursue strategic acquisitions to expand its product portfolio and geographic reach. Acquiring companies with complementary technologies or market access can accelerate Bachem's growth and enhance its competitive position. For example, acquiring a company with expertise in oligonucleotide APIs would strengthen Bachem's position in this rapidly growing market segment. These acquisitions could be completed within the next 3-5 years.
- Strengthening partnerships with pharmaceutical companies: Bachem can strengthen its partnerships with pharmaceutical companies to secure long-term supply agreements and collaborative development projects. By becoming a preferred supplier for key pharmaceutical companies, Bachem can ensure a stable revenue stream and gain access to new drug development opportunities. These partnerships can also lead to the development of innovative peptide-based therapeutics, further driving Bachem's growth.
- Investing in research and development: Bachem can invest in research and development to develop new and innovative peptide and oligonucleotide APIs. By staying at the forefront of technological advancements, Bachem can maintain its competitive edge and attract new customers. This includes exploring novel peptide synthesis methods and developing APIs for emerging therapeutic targets. These R&D investments will likely yield results within the next 2-3 years.
Opportunities
- Expansion into new therapeutic areas, such as oncology and immunology.
- Increasing demand for peptide-based therapeutics.
- Strategic acquisitions to expand product portfolio and geographic reach.
- Strengthening partnerships with pharmaceutical companies.
Threats
- Competition from other API manufacturers.
- Changes in regulatory requirements.
- Economic downturns affecting pharmaceutical spending.
- Technological advancements rendering existing products obsolete.
Competitive Advantages
- Specialized expertise in peptide and oligonucleotide synthesis.
- Strong regulatory compliance and quality control.
- Long-standing relationships with pharmaceutical companies.
- Vertical integration ensures a reliable supply chain.
About BCHMF
Founded in 1971 and headquartered in Bubendorf, Switzerland, Bachem Holding AG has evolved into a prominent player in the global pharmaceutical and biotechnology industry. The company specializes in the development, production, and regulatory support of peptide and oligonucleotide active pharmaceutical ingredients (APIs). Bachem's core business revolves around providing products and services to pharmaceutical and biotechnology companies, supporting them from the research phase through clinical development and commercial application. Bachem's product portfolio includes both new chemical entities (NCEs) and generics, catering to a wide range of therapeutic needs. The company offers a comprehensive suite of services, including project management, quality and regulatory support, analytical services, and good manufacturing practice (GMP) production. Bachem's commitment to vertical integration ensures a reliable supply chain and enhances its ability to meet the evolving needs of its clients. Bachem has established a strong global presence, serving clients worldwide. The company's focus on innovation, quality, and regulatory compliance has earned it a reputation as a trusted partner in the pharmaceutical and biotechnology industries. With a workforce of 2207 employees, Bachem continues to invest in its infrastructure and capabilities to maintain its competitive edge and drive future growth.
What They Do
- Develops peptide active pharmaceutical ingredients (APIs).
- Produces oligonucleotide APIs.
- Provides regulatory support for peptide and oligonucleotide APIs.
- Offers commercial new chemical entities (NCEs).
- Manufactures generic peptide APIs.
- Provides project management services for pharmaceutical development.
- Offers quality control and analytical services.
- Provides GMP production services.
Business Model
- Develops and manufactures peptide and oligonucleotide APIs for pharmaceutical and biotechnology companies.
- Generates revenue through the sale of APIs and related services.
- Offers both custom synthesis and catalog products.
- Focuses on long-term partnerships with pharmaceutical companies.
Industry Context
Bachem Holding AG operates in the chemicals industry, specifically focusing on peptide and oligonucleotide APIs. The pharmaceutical and biotechnology industries are experiencing significant growth, driven by increasing demand for novel therapeutics and personalized medicine. The competitive landscape includes companies such as ARKAF, COIHF, COIHY, FUPEF, and FUPPF, which offer similar products and services. Bachem differentiates itself through its focus on quality, regulatory compliance, and vertical integration, positioning it as a reliable partner for pharmaceutical and biotechnology companies.
Key Customers
- Pharmaceutical companies developing peptide-based therapeutics.
- Biotechnology companies researching and developing new drugs.
- Generic drug manufacturers requiring peptide APIs.
- Research institutions conducting peptide-related studies.
Financials
Chart & Info
Bachem Holding AG (BCHMF) stock price: Price data unavailable
Latest News
No recent news available for BCHMF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BCHMF.
Price Targets
Wall Street price target analysis for BCHMF.
MoonshotScore
What does this score mean?
The MoonshotScore rates BCHMF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Anne-Kathrin Stoller
CEO
Anne-Kathrin Stoller is the CEO of Bachem Holding AG, responsible for leading the company's strategic direction and overseeing its global operations. Her background includes extensive experience in the pharmaceutical and biotechnology industries, with a focus on manufacturing and supply chain management. Prior to joining Bachem, she held leadership positions at several multinational pharmaceutical companies, where she was responsible for driving operational excellence and improving supply chain efficiency. She holds an advanced degree in Chemical Engineering.
Track Record: Since assuming the role of CEO, Anne-Kathrin Stoller has focused on strengthening Bachem's market position and driving sustainable growth. Key achievements under her leadership include expanding the company's manufacturing capacity, enhancing its quality control processes, and forging strategic partnerships with key pharmaceutical companies. She has also overseen the successful launch of several new peptide APIs, contributing to the company's revenue growth and profitability.
BCHMF OTC Market Information
The OTC Other tier, where Bachem Holding AG (BCHMF) trades, represents the lowest tier of the over-the-counter (OTC) market. Unlike stocks listed on major exchanges like the NYSE or NASDAQ, companies on the OTC Other tier often have limited financial disclosure requirements and may not meet the minimum listing standards of the major exchanges. This tier typically includes companies that are distressed, in bankruptcy, or have chosen not to comply with stricter reporting standards. Investing in OTC Other stocks carries significantly higher risks due to the lack of transparency and regulatory oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in BCHMF.
- Low trading volume can lead to price volatility and difficulty in exiting positions.
- The OTC Other tier has less regulatory oversight than major exchanges.
- Potential for fraud or manipulation is higher on the OTC market.
- BCHMF may not meet the minimum listing standards of major exchanges.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal standing.
- Check for any red flags, such as pending lawsuits or regulatory investigations.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Bachem Holding AG is a well-established company with a long operating history.
- The company has a global presence and serves clients worldwide.
- Bachem is a leader in the peptide and oligonucleotide API market.
- The company has a strong focus on quality and regulatory compliance.
Common Questions About BCHMF
What does Bachem Holding AG do?
Bachem Holding AG specializes in the development, production, and regulatory support of peptide and oligonucleotide active pharmaceutical ingredients (APIs). The company serves pharmaceutical and biotechnology companies worldwide, providing them with both commercial new chemical entities (NCEs) and generics. Bachem's comprehensive services cover the entire drug development lifecycle, from research to commercial application, making it a key partner for companies seeking to develop peptide-based therapeutics.
What do analysts say about BCHMF stock?
Analyst consensus on BCHMF is pending further AI analysis. Key valuation metrics to consider include the company's P/E ratio of 30.40, which suggests a premium valuation, and its profit margin of 21.4%, which indicates strong profitability. Growth considerations include the increasing demand for peptide-based therapeutics and the company's expansion into new markets. Investors should monitor Bachem's ability to maintain its market share and manage its cost structure effectively. No buy or sell recommendations are made here.
What are the main risks for BCHMF?
The main risks for Bachem Holding AG include competition from other API manufacturers, which could erode market share and pricing power. Changes in regulatory requirements could increase compliance costs and delay product approvals. Economic downturns could affect pharmaceutical spending, reducing demand for Bachem's products. Fluctuations in raw material prices could impact profitability. Additionally, technological advancements could render existing products obsolete, requiring ongoing investment in research and development.
What are the key factors to evaluate for BCHMF?
Bachem Holding AG (BCHMF) currently holds an AI score of 46/100, indicating low score. Key strength: Leading position in the peptide and oligonucleotide API market.. Primary risk to monitor: Potential: Competition from other API manufacturers could erode market share.. This is not financial advice.
How frequently does BCHMF data refresh on this page?
BCHMF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BCHMF's recent stock price performance?
Recent price movement in Bachem Holding AG (BCHMF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Leading position in the peptide and oligonucleotide API market.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BCHMF overvalued or undervalued right now?
Determining whether Bachem Holding AG (BCHMF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BCHMF?
Before investing in Bachem Holding AG (BCHMF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC market data may be less reliable than exchange-listed data.
- AI analysis is pending for BCHMF.